A BRCA1 or BRCA2 mutation is not a diagnosis of cancer. It is a piece of information about risk, and it is one you can act on. The most important steps are to confirm the result with a certified genetics professional, get a personalized risk assessment based on your specific mutation and family history, and then choose among several established options for surveillance, risk-reducing medication, or risk-reducing surgery. There is no single right answer. There is a right process, and it starts with understanding what your result does and does not mean.
What Does a BRCA1 or BRCA2 Mutation Actually Mean?
BRCA1 and BRCA2 are genes that normally help repair damaged DNA. When either gene carries a harmful mutation, that repair process is impaired, and cells are more likely to accumulate the kind of genetic errors that can lead to cancer.
This raises risk. It does not determine fate. Most people with a BRCA mutation never develop cancer, and the level of risk varies widely depending on which gene is affected, where the mutation sits, and what else is in your family history.
Risk is also not the same for BRCA1 and BRCA2. Research consistently shows that BRCA1 mutations are associated with somewhat higher lifetime breast cancer risk than BRCA2, while BRCA2 mutations are associated with higher ovarian cancer risk in some analyses. Both genes are linked to increased risk of breast and ovarian cancer, and both are associated with pancreatic cancer and, for BRCA2, prostate cancer and melanoma.
Men can carry and pass on these mutations too. A man with a BRCA mutation faces elevated risk of prostate cancer, pancreatic cancer, and male breast cancer, though male breast cancer remains uncommon in absolute terms.
Who Should You See After a Positive BRCA Result?
A certified genetic counselor is the first stop. If your test was ordered through a direct-to-consumer service or a non-specialist, the result needs confirmation in a clinical lab before any decisions are made. Consumer tests sometimes report variants of uncertain significance, which are not the same as a confirmed harmful mutation.
A genetic counselor will:
- Confirm the specific mutation and what is known about it
- Review your family history in detail
- Estimate your personal risk range
- Explain which screening and risk-reduction options apply to you
- Discuss what your result means for relatives who may share it
From there, most people are referred to a multidisciplinary team. That typically includes a breast specialist or breast surgeon, a gynecologic oncologist, and sometimes a medical oncologist. Some centers have dedicated high-risk clinics that coordinate all of this in one place.
The order matters. Seeing a surgeon before you have a full risk assessment can push you toward a decision before you have the information to make it well.
What Are the Screening Options for BRCA Carriers?
Enhanced surveillance aims to find cancer early, when treatment tends to be more effective. It does not prevent cancer. That distinction matters.
For breast screening, guidelines from major cancer organizations generally recommend that BRCA carriers begin annual breast MRI (with contrast) at a younger age than the general population, often alongside annual mammography. The two imaging methods catch different things, which is why they are frequently used together rather than one replacing the other.
For ovarian cancer, the picture is harder. There is no screening test for ovarian cancer that has been shown to reduce deaths in BRCA carriers. Some clinicians use transvaginal ultrasound and a blood test called CA-125, but the evidence that this combination saves lives is weak. Many guidelines note that surveillance for ovarian cancer is not a substitute for risk-reducing surgery, and some do not recommend it at all outside of research settings.
This is one of the more uncomfortable realities of BRCA care. Breast screening works reasonably well. Ovarian screening largely does not.
What Is Risk-Reducing Surgery and When Is It Considered?
Risk-reducing surgery is the most effective way to lower cancer risk in BRCA carriers. It does not eliminate risk entirely.
Risk-reducing mastectomy lowers breast cancer risk substantially. Studies consistently show a large reduction, though not to zero, because some breast tissue can remain after surgery. It is typically offered as an option rather than a requirement, and many carriers choose enhanced screening instead. The decision often hinges on family history, prior biopsies, gene type, and personal tolerance for uncertainty.
Risk-reducing salpingo-oophorectomy removes the fallopian tubes and ovaries. This is the main way to reduce ovarian cancer risk, and it also lowers breast cancer risk in BRCA2 carriers to some degree. Because removing ovaries triggers surgical menopause, timing is a real trade-off. Guidelines generally suggest discussing this surgery after childbearing is complete, often in the late 30s to early 40s for BRCA1 carriers and somewhat later for BRCA2, but the right age depends on individual factors.
A newer approach called salpingectomy with delayed oophorectomy — removing the fallopian tubes first and the ovaries later — is being studied. It is not yet established as equivalent to full removal. Anyone considering it should understand it is an area of active research, not a settled standard.
Are There Medications That Lower BRCA-Related Risk?
Yes, for breast cancer. Drugs called selective estrogen receptor modulators and aromatase inhibitors have been studied for risk reduction in women at elevated breast cancer risk, including some BRCA carriers.
The evidence is strongest for tamoxifen in BRCA2 carriers and less clear for BRCA1 carriers, because BRCA1-associated tumors are more often estrogen-receptor negative and these drugs work by blocking estrogen signaling. Some research suggests a benefit in BRCA1 as well, but the data are not as consistent.
These medications are not without side effects. Tamoxifen carries a small increased risk of blood clots and endometrial cancer. Aromatase inhibitors are associated with bone loss and joint symptoms. Whether the trade-off makes sense depends on your age, gene, other health conditions, and how you weigh the risks.
No medication has been shown to reduce ovarian cancer risk in BRCA carriers.
What Should You Know About Family Implications?
BRCA mutations are inherited in what is called an autosomal dominant pattern. That means each child of a parent with a BRCA mutation has a 50 percent chance of inheriting it, regardless of sex.
This is often the part people find hardest. Sharing the information with relatives can be emotionally complicated, and some family members may not want to know. Genetic counselors can help you plan how and when to have those conversations. Testing for adult relatives is generally offered to adults, since the cancer risks associated with BRCA mutations typically emerge in adulthood.
If you tested positive and your result came from a clinical lab, your relatives can often be tested for the exact same mutation rather than undergoing full panel testing. That is faster and cheaper.
What About Lifestyle Factors?
No lifestyle change has been shown to eliminate or dramatically reduce BRCA-related cancer risk. Anyone who tells you otherwise is overstating what is known.
That said, general health behaviors still matter for overall health. Maintaining a healthy weight, limiting alcohol, staying physically active, and not smoking are associated with lower risk of several cancers in the general population. Whether these factors modify risk specifically in BRCA carriers is an area of ongoing study, and the evidence is not strong enough to make specific promises.
Alcohol intake has been linked to breast cancer risk in the general population. Some research suggests a similar relationship in BRCA carriers, but the data are less consistent. Avoiding or limiting alcohol is a reasonable general health choice, not a proven BRCA-specific strategy.
Breastfeeding and parity have been studied as possible modifiers of BRCA risk. Findings have been mixed and sometimes contradictory between BRCA1 and BRCA2. No clinical guideline currently recommends changing reproductive plans based on BRCA status alone.
Frequently Asked Questions
Does a BRCA mutation mean I will get cancer?
No. A BRCA mutation raises risk, but most carriers never develop cancer. Your actual risk depends on the specific gene, the mutation, and your family history.
What is the first thing I should do after a positive BRCA test?
See a certified genetic counselor to confirm the result and get a personalized risk assessment. Decisions about screening or surgery should follow that assessment, not come before it.
Can men have BRCA mutations?
Yes. Men can inherit and pass on BRCA1 or BRCA2 mutations, and carriers face elevated risk of prostate, pancreatic, and male breast cancer.
Is ovarian cancer screening effective for BRCA carriers?
No screening test for ovarian cancer has been shown to reduce deaths in BRCA carriers. This is why risk-reducing surgery is often discussed as the more reliable option.

